Study of the Adrenergic Heart Innervation With Iodine 123–Metaiodobenzylguanidine in Heart Failure Before Transplantation

Llorca, Cristina; Bonet, Luis Almenar; Conejero, J.L. Vercher; Dólera, T. Mut; Arroyo, C. Olivas; Dolz, Luis Martínez; Salvador, Antonio; Navarro, A.E.

doi:10.1016/j.transproceed.2008.08.107

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Historically, because of a delayed national consensus on this treatment and because there are few donors, Japan has much less experience with heart transplantation per se than other countries and, therefore, has no significant clinical data on cardiac 123 I-MIBG imaging for this treatment. Nevertheless, compared with other, standard parameters, cardiac 123 I-MIBG imaging may contribute to improvements in determining the necessity of heart transplantation and expected survival interval (3,12,68,69) in an era when advanced device therapy, optimal drug treatment, and cardiac 123 I-MIBG imaging are available. Cardiac 123 I-MIBG imaging may be also useful for the assessment of reinnervation in transplanted hearts.…”

Section: Cardiac 123 I-mibg Imaging In Heart Transplantationmentioning

confidence: 99%

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Nakajima

Nakata

2015

J Nucl Med

View full text Add to dashboard Cite

Cardiac neuroimaging with 123 I-metaiodobenzylguanidine ( 123 I-MIBG) has been officially used in clinical practice in Japan since 1992. The nuclear cardiology guidelines of the Japanese Circulation Society, revised in 2010, recommended cardiac 123 I-MIBG imaging for the management of heart failure (HF) patients, particularly for the assessment of HF severity and prognosis of HF patients. Consensus in North American and European countries regarding incorporation into clinical practice, however, has not been established yet. This article summarizes 22 y of clinical applications in Japan of 123 I-MIBG imaging in the field of cardiology; these applications are reflected in cardiology guidelines, including recent methodologic advances. A standardized cardiac 123 I-MIBG parameter, the heartto-mediastinum ratio (HMR), is the basis for clinical decision making and enables common use of parameters beyond differences in institutions and studies. Several clinical studies unanimously demonstrated its potent independent roles in prognosis evaluation and risk stratification irrespective of HF etiologies. An HMR of less than 1.6−1.8 and an accelerated washout rate are recognized as high-risk indicators of pump failure death, sudden cardiac death, and fatal arrhythmias and have independent and incremental prognostic values together with known clinical variables, such as left ventricular ejection fraction and brain natriuretic peptide. Another possible use of this imaging technique is the selection of therapeutic strategy, such as pharmacologic treatment and nonpharmacologic treatment with an implantable cardioverter-defibrillator or cardiac resynchronization device; however, this possibility remains to be investigated. Recent multiple-cohort database analyses definitively demonstrated that patients who were at low risk for lethal events and who were defined by an HMR of greater than 2.0 on 123 I-MIBG studies had a good long-term prognosis. Future investigations of cardiac 123 I-MIBG imaging will contribute to better risk stratification of low-risk and high-risk populations, to the establishment of costeffective use of this imaging technique for the management of HF patients, and to worldwide acceptance of this imaging technique in clinical cardiology practice.

show abstract

Section: Cardiac 123 I-mibg Imaging In Heart Transplantationmentioning

confidence: 99%

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Nakajima

Nakata

2015

J Nucl Med

View full text Add to dashboard Cite

show abstract

Study of the Adrenergic Heart Innervation With Iodine 123–Metaiodobenzylguanidine in Heart Failure Before Transplantation

Cited by 1 publication

References 3 publications

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Contact Info

Product

Resources

About

Study of the Adrenergic Heart Innervation With Iodine 123–Metaiodobenzylguanidine in Heart Failure Before Transplantation

Cited by 1 publication

References 3 publications

Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Contact Info

Product

Resources

About

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan